Vascular-targeted agents for the treatment of angiosarcoma

First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: Pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials

“…However, despite limited clinical responses reported thus far to treatment with VEGF targeted agents, angiosarcoma response to vascular targeted agents is of continued interest [34,35]. Therapies currently in pre-clinical study include Rho-kinase inhibitors [36] and vascular disrupting agents [37]. Our analysis provides a useful measure of angiosarcoma response to chemotherapy for comparison with future clinical trials.…”

Inhibition of heat shock protein 90 exerts an antitumour effect in angiosarcoma: involvement of the vascular endothelial growth factor signalling pathway

“…In clinical practice, taxanes are an effective therapy for patients with angiosarcoma . Paclitaxel has been reported to inhibit the proliferation of angiosarcoma cell lines, such as ASM and ISO‐HAS, in an experimental setting . Thus, we analysed the inhibitory effect of taxane monotherapy, and also combination therapy with ganetespib and taxane, in angiosarcoma cells.…”

“…3,4 Paclitaxel has been reported to inhibit the proliferation of angiosarcoma cell lines, such as ASM and ISO-HAS, in an experimental setting. 31 Thus, we analysed the inhibitory effect of taxane monotherapy, and also combination therapy with ganetespib and taxane, in angiosarcoma cells. Both paclitaxel and docetaxel showed a significant inhibitory effect in angiosarcoma cells in a dose-dependent manner (Fig.…”

Angiosarcoma of the Prostate Gland following Brachytherapy for Prostatic Adenocarcinoma

“…Taxanes are often used given their anti-angiogenic nature. Novel vascular-targeting agents such as bevacizumab (anti-VEGF antibody), axitinib (VEGF-receptor tyrosine kinase inhibitor) and vadimezan (vascular-disrupting agent) are being evaluated in the management of angiosarcoma in laboratory models [10]. Our patient had locally advanced cancer with negative surgical margins after radical cystoprostatectomy, and received multiple chemotherapeutic agents; unfortunately his disease is still not cured.…”